TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683404

Intervention type: DEVICE
Intervention: Electrochemotherapy (ECT)
Description: Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.

Intervention type: DRUG
Intervention: Bleomycin
Description: Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
Study: NCT01048333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol Turbuhaler 9 μg and Placebo Diskus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler
Study: NCT03929939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training and healthy eating (overseen by IEEM research team)
Description: Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan).
Study: NCT02883790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Somnage
Description: Melatonin 1mg, Zinc, Magnesium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02472678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based tailored information and support system
Description: Access to the web-based tailored information and support system (with a username/password)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The control group will receive standard care.
Study: NCT04887883

Intervention type: BEHAVIORAL
Intervention: Resistance exercise
Description: Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.

Intervention type: BEHAVIORAL
Intervention: Resistance exercise
Description: Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
Study: NCT00762957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and metformin
Description: TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and metformin
Description: TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
Study: NCT04495491

Intervention type: OTHER
Intervention: pupillary block group
Description: According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.

Intervention type: OTHER
Intervention: plateau iris group
Description: According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.

Intervention type: OTHER
Intervention: mixing mechanism group
Description: According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
Study: NCT04126057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightGlass Vision DOT Spectacle Lenses
Description: Subjects randomized to test vs control, left eyes and right eyes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightGlass Vision DOT Spectacle Lenses
Description: Subjects randomized to test vs control, left eyes and right eyes
Study: NCT04633837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracellular Matrix Graft Injectable Implant
Description: The extracellular matrix injectable implant will serve as the intervention in this study.
Study: NCT04450303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth CBT
Description: The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
Study: NCT03778047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral
Study: NCT01654718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg Delayed release tablets (Test Product)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Study: NCT02401048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT03778047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC1119
Description: oral
Study: NCT02401048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study: NCT02907918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * Or FDA approved biosimilar~* Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research tumor biopsy
Description: Baseline, cycle 1 day 15, and surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research bone marrow (OPTIONAL)
Description: Baseline and surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
Study: NCT02807636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study: NCT02907918

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Research blood for germline DNA
Description: Baseline
Study: NCT03776032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection once a week
Study: NCT02907918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for detection of circulating tumor cells
Description: Baseline
Study: NCT03776032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
Study: NCT01829477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride tablet.
Study: NCT00170625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin
Description: Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin
Description: Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
Study: NCT02389387

Intervention type: OTHER
Intervention: Intensive Intervention
Description: I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
Study: NCT04387019

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sampling from peripheral vein

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sampling from peripheral vein

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sampling from peripheral vein
Study: NCT01019395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
Study: NCT02807636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study: NCT01019395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
Study: NCT03935776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factors Modification Programme
Description: 12- week supervised risk factor modification programme derived from the Euroaction study standards

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Healthcare
Description: Patients are advised to adjust lifestyle without the support of the structured supervised programme
Study: NCT02919423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Study: NCT03262857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of magnesium sulfate with lidocaine in inferior alveolar nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of magnesium sulfate with lidocaine in inferior alveolar nerve block
Study: NCT02613819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy.
Study: NCT03388749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Study: NCT04135157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoralis nerve block II
Description: PECS II block will be performed 30 min. before general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spine plane block
Description: ESP block will be performed 30 minutes before general anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Only general anesthesia will be performed.
Study: NCT02007434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study: NCT03846154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive family intervention including individual sessions of FORNET
Description: 1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance /.) If needed, legal assistance
Study: NCT03686228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PB-MNC therapy
Description: The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No-PB-MNC therapy
Description: Patients will receive ASA 81 mg once daily and wound care and pain killer drug
Study: NCT02007434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study: NCT01319656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support, management, educational, counselling, follow-up
Description: The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support, management, educational, counselling, follow-up
Description: The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
Study: NCT01204320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Balloon
Description: POBA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting Stent
Description: Stenting
Study: NCT01079676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (Eurofarma)
Description: Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim (Granulokine, Amgen)
Description: Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
Study: NCT03867812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOBAR
Description: SOBAR is a high protein nutrition bar optimized to delay gastric emptying

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control food
Description: Chexmix (General Mills Inc.), Honey Nut Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full meal
Description: Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
Study: NCT01134445

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Proxima™ Hip
Description: A short, anatomic, cementless femoral component for use in total hip arthroplasty
Study: NCT06194370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training by BOPPPS Teaching Model
Description: Training by BOPPPS Teaching Model

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training Regularly
Description: Training Regularly
Study: NCT01209585

Intervention type: OTHER
Intervention: Blood samples
Description: Subjects will have visits on Days 1, 30 and 120.
Study: NCT01209585

Intervention type: OTHER
Intervention: Blood samples
Description: Subjects will have visits on Days 1, 30 and 120.

Intervention type: OTHER
Intervention: Synovial fluid aspiration
Description: Subjects will have visits on Days 1, 30, and 120.

Intervention type: OTHER
Intervention: Synovial fluid aspiration
Description: Subjects will have visits on Days 1, 30, and 120.

Intervention type: OTHER
Intervention: Synovial tissue sample
Description: Subjects will have visits on Days 1, 30, and 120.
Study: NCT02007434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine 10 mg orally from Day -7 until Day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: Loratadine 10 mg orally from Day -7 until Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
Study: NCT03964038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gilteritinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib mini tablet
Description: oral
Study: NCT02007434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Chin Strap
Description: A compression chin strap was applied 15 minutes after dosing for at least 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compression Chin Strap
Description: A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
Study: NCT00855062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: 100 mg capsule every 12 hours by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: minocycline placebo capsule
Description: 1 capsule every 12 hours by mouth